home / openregs

documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

comment_end_date
A FULL UTC INSTANT, not a calendar date, despite the column name: '2026-08-29T03:59:59Z' is 11:59:59 PM EASTERN on 2026-08-28. Federal comment periods close at 11:59:59 PM Eastern, so the UTC calendar date is ONE DAY LATER than the official deadline on every end-of-day close — 444,689 of the 444,690 populated rows (measured 2026-09-06). Convert to America/New_York before presenting a deadline, and compare with julianday(comment_end_date) > julianday('now'): a plain > datetime('now') is a TEXT comparison between two different formats and keeps already-closed dockets matching for up to ~20 hours. The sibling column on open_comments.documents WAS corrected to an Eastern calendar date (queue #498); this one is unchanged and still an instant — the two databases do not agree on grain. (queue #644)
comment_start_date
A FULL UTC INSTANT, not a calendar date, despite the column name — same grain as comment_end_date on this table. Convert to America/New_York before presenting it. (queue #644)

44 rows where docket_id = "FDA-2025-P-1807" sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

posted_year 2

  • 2025 42
  • 2026 2

document_type 2

  • Supporting & Related Material 39
  • Other 5

agency_id 1

  • FDA 44
id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2025-P-1807-0369 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 Amendment and Supplement from Interest of Justice Other Amendment 2026-09-30T04:00:00Z 2026 9 2026-09-30T04:00:00Z   2026-09-30T22:49:09Z   0 0 09000064b95f0cdd
FDA-2025-P-1807-0368 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 Response Letter Other Response(s) 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:11:17Z   0 0 09000064b955ee1b
FDA-2025-P-1807-0365 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 Interim Response to Interest of Justice Other Response(s) 2025-12-12T05:00:00Z 2025 12 2025-12-12T05:00:00Z   2025-12-12T21:12:16Z   0 0 09000064b90c915d
FDA-2025-P-1807-0033 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 21a - Executive Order 13139 Wikisource the free online library Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:35:11Z   0 0 09000064b8e1f1d8
FDA-2025-P-1807-0038 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 24 - National Security Presidential Memorandum NSPM 2 The White House Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:36:22Z   0 0 09000064b8e1f1fc
FDA-2025-P-1807-0040 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 25 - STATUTE 67 Pg. 631 Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:36:41Z   0 0 09000064b8e1f201
FDA-2025-P-1807-0020 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 12a - U.S. Department of Defense _ Contract Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:28:11Z   0 0 09000064b8e1d4a3
FDA-2025-P-1807-0009 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 3 - Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derive Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:25:58Z   0 0 09000064b8e1dd5b
FDA-2025-P-1807-0015 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 8- Moderna Inc 2018 form S1 registration statement US securities and Exchange Commission_compressed Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:27:09Z   0 0 09000064b8e3d122
FDA-2025-P-1807-0025 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 15a - GAO-21-387 highlights Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:33:00Z   0 0 09000064b8e1f1c8
FDA-2025-P-1807-0027 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 16a - GAO 21 108 Highlights DEFENSE PRODUCTION ACT Opportunities Exist to Increase Transparency and Identify Future Actions Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:33:31Z   0 0 09000064b8e1f1cc
FDA-2025-P-1807-0034 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 22 - Executive Order 13989 Ethics Commitments by Executive Branch Personnel The American Presidency Project Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:35:34Z   0 0 09000064b8e1f1f0
FDA-2025-P-1807-0011 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 5 - Journal of Molecular Biology _ ScienceDirect_com by Elsevier Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:26:20Z   0 0 09000064b8e1d49d
FDA-2025-P-1807-0019 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 12 - Pfizer-Inc.-Covid-19-Vaccine-Contract Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:28:01Z   0 0 09000064b8e1d4a2
FDA-2025-P-1807-0016 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 9 - ii Moderna Inc 2019 Form 10K annual Report US Securities and Exchange Commission_compressed Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:27:25Z   0 0 09000064b8e3d219
FDA-2025-P-1807-0017 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 10 - iii NioNtech SE 2019 Form F1 Registration Statement US Securities And Exchange Commission_compressed Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:27:39Z   0 0 09000064b8e3d21e
FDA-2025-P-1807-0012 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 6 - Nature Biotechnology Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:26:31Z   0 0 09000064b8e1d49e
FDA-2025-P-1807-0018 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 11 - Opening Ceremony World Health Summit 2021 Speech Stefan Oelrich Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:27:52Z   0 0 09000064b8e1d4a1
FDA-2025-P-1807-0021 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 13 - Award Contract No W911QY20C0100 by and between Moderna US Moderna Inc. - Business Contracts Justia Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:28:21Z   0 0 09000064b8e1f1c4
FDA-2025-P-1807-0024 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 15 - GAO-21-387_compressed Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:29:00Z   0 0 09000064b8e1f1c7
FDA-2025-P-1807-0030 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 19 - Advanced Biological Research Group to Study Effects of mRNA on Women's Reproduction _ Morningstar Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:34:35Z   0 0 09000064b8e1f1d5
FDA-2025-P-1807-0031 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 20 - Whistleblower Doctor Drops Bombshell on mRNA COVID19 Vaccines But Whats the Evidence Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:34:46Z   0 0 09000064b8e1f1d6
FDA-2025-P-1807-0032 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 21 - 64 FR 54175 Improving Health Protection of Military Personnel Participating in Particular Military Operations Content Details Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:34:56Z   0 0 09000064b8e1f1d7
FDA-2025-P-1807-0036 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 23 - Executive Order 14102 Ordering the Selected Reserve and Certain Members of the Individual Ready Reserve of the Armed Forces to Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:35:57Z   0 0 09000064b8e1f1f6
FDA-2025-P-1807-0004 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 1 - Evidence of admin remedy absolved IOJ Cit Pet 2023 FDA_compressed Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T22:37:42Z   0 0 09000064b8e1dd56
FDA-2025-P-1807-0005 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 WHO Ethics Complaints Sept 18 2024 To MDS EUL Referred to National Authority Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:24:46Z   0 0 09000064b8e1dd57
FDA-2025-P-1807-0006 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 1 - Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:25:00Z   0 0 09000064b8e1dd58
FDA-2025-P-1807-0008 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 2025-05-21-Chairman-Ron-Johnson-Opening-Statement-FINAL Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:25:44Z   0 0 09000064b8e1dd5a
FDA-2025-P-1807-0022 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 13a - U.S. Department of Defense _ Contract Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:28:35Z   0 0 09000064b8e1f1c5
FDA-2025-P-1807-0029 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 18 - 2021-04-08_Clyburn to Hatfill re PPE Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:34:23Z   0 0 09000064b8e1f1d4
FDA-2025-P-1807-0037 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 23a - Federal Register Ordering the Selected Reserve and Certain Members of the Individual Ready Reserve of the Armed Forces to Acti Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:36:10Z   0 0 09000064b8e1f1fb
FDA-2025-P-1807-0003 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 1 - Department of Defense - FOIA Requests from IOJ Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T22:06:35Z   0 0 09000064b8e1dd55
FDA-2025-P-1807-0001 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 Acknowledgment Letter from FDA DMB to Interest of Justice Other Acknowledgement Letter/Receipt 2025-06-27T04:00:00Z 2025 6 2025-06-27T04:00:00Z   2025-06-27T22:04:17Z   0 0 09000064b8e1ef83
FDA-2025-P-1807-0002 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 Petition for Reclassification from Interest of Justice Other Petition(s) 2025-06-27T04:00:00Z 2025 6 2025-06-27T04:00:00Z   2025-12-18T10:00:13Z   1 0 09000064b8e1ef7d
FDA-2025-P-1807-0010 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 4 - Current Issues in Molecular Biology _ An Open Access Journal from MDPI Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:26:07Z   0 0 09000064b8e1d49c
FDA-2025-P-1807-0013 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 7 - Genome-wide host-pathogen analyses reveal genetic interaction points in tuberculosis disease _ Nature Communications Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:26:44Z   0 0 09000064b8e1d49f
FDA-2025-P-1807-0007 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 2 - Immune imprinting breadth of variant recognition and germinal center response in human SARS CoV2 infection and vaccination Cell Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:25:15Z   0 0 09000064b8e1dd59
FDA-2025-P-1807-0023 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 14 - JAMS_7_Packard Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:28:49Z   0 0 09000064b8e1f1c6
FDA-2025-P-1807-0028 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 17 - Steven Hatfill Dana parish They Lied Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:33:43Z   0 0 09000064b8e1f1cf
FDA-2025-P-1807-0039 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 24a - National Security Memorandum (NSM) on Artificial Intelligence Democracy Tech Initiative Markup - DFRLab Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:36:31Z   0 0 09000064b8e1f1fd
FDA-2025-P-1807-0041 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 26 - RFK Jr. seeks to remove COVID-19 vaccine recommendation for children Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:36:50Z   0 0 09000064b8e1f202
FDA-2025-P-1807-0014 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 8 - Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine _ New England Journal of Medicine Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:26:58Z   0 0 09000064b8e1d4a0
FDA-2025-P-1807-0026 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 16 - GAO 21 108 DEFENSE PRODUCTION ACT Opportunities Exist to Increase Transparency and Identify Future Actions to Mitigate Medical Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:33:14Z   0 0 09000064b8e1f1ca
FDA-2025-P-1807-0035 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 22a - Federal Register Initial Rescissions of Harmful Executive Orders and Actions Supporting & Related Material Background Material 2025-06-27T04:00:00Z 2025 6     2025-06-27T19:35:44Z   0 0 09000064b8e1f1f5

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;
Powered by Datasette · Queries took 2.702ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API · Privacy